Fierce Biotech1 min read
saveVor pays RemeGen $10M for long-acting addition to autoimmune pipeline
Vor Bio is paying RemeGen $10 million upfront in cash for rights to RC298 outside Greater China, adding a long-acting drug candidate to its BAFF/APRIL franchise.
comments(0)
5-min edit window · permanent after that